any data of PD-1 or PD-L1 inhibitor in BAC (or adenocarcinoma in situ) patients - 1270033

5 posts / 0 new
Last post
jasmine
any data of PD-1 or PD-L1 inhibitor in BAC (or adenocarcinoma in situ) patients - 1270033

Read the post about PD-1 inhibitor in adenocarcinoma in lung. Curious to learn if the studies enrolled any subjects with BAC (or adenocarcinoma in situ). It seems BAC is not the study population but want to confirm. It would be great to know whether PD-1 works on BAC.
Many thanks!

jasmine
Reply To: any data of PD-1 or PD-L1 inhibitor in BAC (or

My mom was diagnosed with multi-foci BAC about 5 yrs ago; She underwent wedge-resections of 3 lesions (>1cm) and still have multiple smaller ones in both lungs. Thanks to what we learned at Cancergrace that she did not choose to go thru any chemo post surgery although many doctors in my hometown (in China) challenged us. She had yearly CT f/u and expects this year's CT in Aug. She doesn't have typical symptoms associated with cancer progression, however, she always has to clear up her throat by "dry cough" although there is not any discharge at all. Lately I found her frequency/severity of "dry cough" is going up - more frequent and more pronounced. Is this possibly due to the increasing agitation of the lesion (therefore, disease progression)? Perhaps, I should not worry about this because I guess there is not much can be done even the fact that her cancer is in progression.

catdander
Hi Jasmine,

Hi Jasmine,

I've just noted 2 new videos from Dr. West that address BAC. Since it can come in different forms I'd suggest checking them out. The newest (new 2 videos) are at the top of the list of BAC specific posts/videos, http://cancergrace.org/lung/tag/bronchioloalveolar-carcinoma-bac/

When BAC needs to be treated it's usually treated as adenocarcinoma is treated. Our faculty are at the ASCO meeting this week where much information on the subject of immunotherapy and nsclc is and will be presented. I've read a little on results from patients with squamous nsclc but will need to look for info specific to adeno. If you're up to it you may want to search for info from ASCO as well. But I'll check back in tomorrow with what I learn from a look around.

I hope for the best for you.

Janine

Dr. West is contributing to a live blog about presentations he's attending (mostly lung cancer) this week, http://www.medscape.com/features/content/6006730

catdander
Hi Jasmine,

Hi Jasmine,

I'm sorry to read about your mom's cancer. I'm going to merge your 2 threads since they are so closely related so we can keep track for the conversation.

There should be treatments your mom can take as suggested in the videos linked to. If the cancer remains quite indolent a little treatment can go a long way. I hope this it the case for your mom.

Janine

biggerten
Info out of the ASCO meeting

Info out of the ASCO meeting regarding the PD1 pathway and adeno NSCLC was mostly that PD-1 expression indeed indicated best response to PD-1 drugs (Opdivo from BMS). Merck released data at AACR in April indicating the same, and Roche released data indicating high PD-1 expression resulted in doubling survival in adeno NSCLC with MPDL3280A, a PD-L1 drug that's a little further away from commercialization.

There was encouraging data regarding other cancers, too, with these drugs.

Overnight, Merck announced that the FDA has accepted the sBLA application for Keytruda for adeno NSCLC, target date is October 2, although the FDA responded in about three days last March for Opdivo in squamous NSCLC, let's hope the same level of urgency is still there.

http://www.businesswire.com/news/home/20150601006690/en/FDA-Accepts-Supp...